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Abstract
Hypothesis and Objectives—PEGylated liposomal blood pool contrast agents maintain contrast
enhancement over several hours. This study aimed to evaluate (long-term) imaging of pulmonary
arteries, comparing conventional iodinated contrast with a liposomal blood pool contrast agent.
Secondly, visualization of the (real-time) therapeutic effects of tissue-Plasminogen Activator (t-PA)
on pulmonary embolism (PE) was attempted.
Materials and Methods—Six rabbits (approximate 4 kg weight) had autologous blood clots
injected through the superior vena cava. Imaging was performed using conventional contrast
(iohexol, 350 mg I/ml, GE HealthCare, Princeton, NJ) at a dose of 1400 mgI per animal and after
wash-out, animals were imaged using an iodinated liposomal blood pool agent (88 mg I/mL, dose
900 mgI/animal). Subsequently, five animals were injected with 2mg t-PA and imaging continued
for up to 4 ½ hours.
Results—Both contrast agents identified PE in the pulmonary trunk and main pulmonary arteries
in all rabbits. Liposomal blood pool agent yielded uniform enhancement, which remained relatively
constant throughout the experiments. Conventional agents exhibited non uniform opacification and
rapid clearance post injection. Three out of six rabbits had mistimed bolus injections, requiring repeat
injections. Following t-PA, Pulmonary embolus volume (central to segmental) decreased in four of
five treated rabbits (range 10–57%, mean 42%). One animal showed no response to t-PA.
Conclusions—Liposomal blood pool agents effectively identified acute PE without need for re-
injection. PE resolution following t-PA was quantifiable over several hours. Blood pool agents offer
the potential for repeated imaging procedures without need for repeated (nephrotoxic) contrast
injections.
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Introduction
Patients who present with acute chest symptoms are a frequent clinical problem (1,2). This is
partly due to the range of acute diagnoses that can be considered. As a result, early triage to
decide on adequate management is crucial. This has led to a significant increase in CT
utilization (3–6), and attempts are now focusing on reducing the number of patients requiring
imaging (7,8). Essentially, the three most critical diagnoses that clinicians focus on are (1)
myocardial ischemia, (2) pulmonary embolism and (3) aortic dissection or rupture. Although
all three diagnoses can now be evaluated using CT, simultaneous evaluation, or a “triple rule
out” CT protocol, is difficult to entertain due to competing requirements. Since conventional
contrast agents are distributed and cleared within minutes (9–11), effective multifunctional
imaging becomes difficult. Thus, for PE evaluation, the contrast bolus has to be timed to be
optimal in the right heart and pulmonary circulation (12,13), while for assessment of the aorta
and coronary arteries a greater delay from bolus to imaging is required to reach optimal contrast
enhancement in the left heart.
A correctly timed contrast bolus delay is not easy to achieve, even with the aid of a test bolus
or bolus detection systems in modern CT scanners, up to 10% of PE studies suffer from sub-
optimal contrast in the pulmonary arteries (8,12–14). Although one could devise a combined
protocol with multiple contrast bolus injections and repeated CT imaging of the relevant field
of view, it is likely that the number of sub-optimal contrast studies will rise. A single study
with optimal, simultaneous enhancement in multiple vascular beds would prevent repeat
studies with their incremental X-ray dose with each scan and the nephrotoxicity of repeat
contrast administration.
Contrary to current conventional CT contrast media, blood pool agents offer a number of
theoretically interesting alternatives. (15,16). First, the contrast can be delivered as a single
slowly injected dose with fewer constraints on optimization of contrast bolus (although the
first pass could still take advantage of this option), thus allowing imaging of the right and left
circulation within a single investigation after a single injection of contrast agent. Second, the
liposomal agents used in this study have been previously shown to clear via the reticulo-
endothelial system (15,16) and not via renal filtration, thus reducing the nephrotoxicity
associated with conventional contrast agents. Finally, a blood pool agent could allow
longitudinal studies to determine the efficacy of (potentially aggressive) treatment, such as
thrombolytic therapy, in acute cardiac ischemia or major pulmonary embolism, without the
need for a second contrast injection (17).
There have been attempts to give more homogeneous (and prolonged) contrast enhancement
using macromolecular agents (10,11) and other contrast carriers (9) However, none can be
defined as a true long-acting blood pool agent. Long circulating liposome-based contrast agents
represent a novel class of blood pool agents for CT imaging (15). This agent consists of a non-
ionic, conventional iodinated contrast agent encapsulated in polyethylene glycol coated
liposomes (PEGylated liposomes). The iodinated liposomal blood pool contrast agent is cleared
by the reticulo-endothelial system, thus reducing the potential for nephrotoxicity and enhancing
their applications in patients who currently would be considered too great a risk for
conventional iodinated contrast agents, such as those with renal impairment (15,18). A previous
study using this agent showed rapid blood pool contrast attenuation in a rabbit model that
remained virtually constant over a 3.5 hour period (15). To test the hypothesis that liposomal
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contrast agent can yield prolonged and diagnostically sufficient enhancement of the pulmonary
circulation, conventional iohexol (Omnipaque 350) was compared with iohexol-encapsulated
liposomal agent (liposomal-iohexol) in a rabbit model of pulmonary embolism before and after
treatment with tissue plasminogen activator (t-PA).
Materials and Methods
Rabbit in-vivo protocol
Following approval by the University of Iowa’s Animal Care and Use Review Committee,
male New Zealand rabbits (weight approximately 4 kg) were sedated using 18 mg of ketamine
and 3mg of xylazine intramuscularly. After peripheral intravenous access was established in
an ear vein, and 10 ml of blood was drawn. Further sedation was given using intravenous
pentobarbital. Eight rabbits were included in this study with all eight receiving autologous
blood clot to induce PE. The initial rabbit survived a 10ml clot with the subsequent two rabbits
succumbing to fatal PE. The embolism protocol was then modified and the clot burden was
then reduced to 1ml or until the embolism could be clearly visualized by standard contrast
imaging. Of the six surviving rabbits, five received thrombolytic treatment and were monitored
for regression of pulmonary embolism, while one control rabbit did not receive thrombolytic
treatment
Preparation of the rabbits included anesthetizing the neck with lidocaine and an open
tracheostomy with a 3Fr endotracheal tube and then placing the rabbit on a ventilator with tidal
volumes of 50ml (12.5ml/kg), respiratory rate of 25/min, PEEP 10 cmH2O, and FIO2 of 100%.
A cut down on the internal jugular vein was performed and a 6Fr central venous introducer
catheter inserted.
The rabbit was then transported to the CT scanner where imaging before and after the induction
of pulmonary embolism was performed. The rabbit was anesthetized during the imaging with
10 mg of pentobarbital intravenously every half hour as needed. At the end of the imaging, the
rabbit was sacrificed using a lethal dose of phenobarbital and phenytoin.
Induction of pulmonary embolism
During placement of the ear vein catheter, 10ml of blood was withdrawn and allowed to clot
in the syringe at room temperature. The first two rabbits in the experiment received 10ml of
clot given through the central line and were successfully imaged. In two subsequent animals,
the massive saddle emboli were lethal, prompting a change in our protocol to agitate the blood
clot to reduce the size of clot particles and only inject 1 ml of clotted blood. This method was
successfully applied in the subsequent five animals.
Thrombolytic therapy protocol
Recombinant tissue plasminogen activator (rt-PA) was chosen because of its clinical
applicability and availability. The dose applied was according to clinical protocols for PE or
acute coronary events, using two bolus injections of 0.5mg/kg at 30 minute intervals through
the central venous catheter line. Following successful imaging of the first control rabbit, this
protocol was applied in the subsequent five experiments and imaging was repeated over time
without further injection of either contrast or rt-PA.
Imaging protocol
A multiple detector row CT system (Sensation 64, Siemens, Forchheim, Germany) in spiral
scanning mode was used with the following parameters: keV 120, mAs 100, pitch 1, and slice
collimation of 64×0.6 mm. The field of view was 10cm and images were reconstructed to fit
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a 512×512 matrix. Vital signs were monitored using ECG and oxygen saturation throughout
the imaging procedure.
Following a base-line non-enhanced study of chest and abdomen, the following order of
imaging (see below) was applied beginning with one base-line study using conventional non-
ionic low-osmolar contrast. After the injection of blood clot, CT pulmonary angiography was
repeated with conventional contrast agent to confirm adequate PE had developed. After a
minimum duration of 30 minutes, the liposomal blood pool agent was used for further CT
pulmonary angiography at the following time points: baseline, 15, 30, 45, 60, 90,105, 165 and
270 minutes after the initial injection of blood pool agent. Tissue-Plasminogen Activator (1
mg/animal) was administered twice (total dose 2 mg/animal) at 15 and 30 minutes after the
baseline blood pool CT pulmonary angiogram.
Contrast agents
Initial, baseline imaging took place using non-ionic low-osmolar contrast (iohexol; Omnipaque
350, GE HealthCare, Princeton, NJ) at a rate of 0.5 ml/min for 8 seconds for a total dose of 1
ml/kg. The total amount of administered Iodine was 1400 mg per animal.
Liposomal-iohexol formulations were fabricated by methods similar to those described
previously (16). Briefly, a lipid mixture consisting of 1,2-Dipalmitoyl-sn-glycero-3-
phosphocholine (DPPC) (Genzyme, MA), Cholesterol (Sigma, St Louis, MO) and 1,2-
distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(poly(ethylene glycol))-2000]
(mPEG2000-DSPE) (Genzyme, MA) in the ratio 55:40:5 was dissolved in ethanol at 60°C.
The ethanol solution was then hydrated with iohexol solution (350 mg I/mL) and stirred for
1½ hr at 70°C. The resulting liposomal solution was sequentially extruded at 70°C on Lipex
Thermoline extruder (Northern Lipids, Vancouver, Canada) with three passes through 0.4 μm
Nuclepore membrane (Waterman, Newton, MA), five passes through 0.2 μm Nuclepore
membrane and eight passes through 0.1 μm Nuclepore membrane. The external phase was then
cleaned and the liposomes simultaneously concentrated by diafiltration using MicroKros
modules (Spectrum Laboratories, CA) of 50 nm cutoff. The size of the resultant liposomal
formulations obtained was determined by dynamic light scattering (DLS) using a Brookhaven
Instruments BI-9000AT Digital Autocorrelator, a BI-200SM goniometer (JDS Uniphase; San
Jose, CA) and a Hamamatsu photomultiplier (supplied by Brookhaven, Long Island, NY). The
resultant size of liposomes in the formulation as determined using DLS was 105 nm with a
polydispersity index of 0.107. The iodine content of the formulation was determined using a
UV spectrophotometer (Libra S32 PC, Biochrom) at 245 nm. The size of the resultant liposomal
formulations obtained was determined by Dynamic Light Scattering using a Brookhaven
Instruments BI-9000AT Digital Autocorrelator, a BI-200SM goniometer (JDS Uniphase; San
Jose, CA) and a Hamamatsu photomultiplier (supplied by Brookhaven, Long Island, NY).
Mean size of liposomes as determined by dynamic light scattering was 93 ± 0.1 nm. The
polydispersity index for the formulation was 0.118. The iodine concentration of the final
formulation was determined as 88 mgI/ml.
The liposomal formulation was transported under refrigerated condition from Texas to the
imaging site in Iowa. Prior to starting the study, the formulation was brought to room
temperature and subsequently administered by hand held injection through the central line with
a total Iodine dose of 900 mg per animal.
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Image analysis
CT images were evaluated for level of contrast opacification of the pulmonary artery using
standard measurements of mean attenuation (Hounsfield Units; HU) over time. Time-
attenuation curves were assessed for contrast enhancement dynamics.
Quantitative analysis of pulmonary embolus burden with both contrast agents and subsequent
response to thrombolytic therapy was performed using an in house developed software system
(Volumetric Imaging Display and Analysis: VIDA) (19), which has a region of interest module
that adjusts hand drawn regions of interest based upon the half-maximum principle. This
method has been used and validated for identifying airway wall borders (20). From a hand
drawn region, the software identifies the ROI’s center of mass and sends a set of rays out from
the center point over a user-determined distance. The voxel values are evaluated along each
ray, a minimum (in this case the clot) and a maximum value (either enhanced contrast around
the clot or the vessel wall) are determined and the user-drawn edge is adjusted to fall at the
half-way point along the maximum and minimum locations. ROIs were drawn at identical slice
positions, with identical window levels and magnification settings. However, the half-max
adjustment is calculated on the original 16 bit image data and thus is not affected by the window
and level settings used to display the images. The edge adjusted ROI was smoothed with a
three point smoothing algorithm and a final volumetric value was calculated by the software,
adding each of the individual 2D ROIs identified on the axial sections spanning the extent of
the clot. Response to thrombolytic treatment was reported as percentage changes in volumetric
measurements from the initial clot burden as measured with the initial liposomal contrast.
Results
Contrast agent comparison
CT image density analysis showed good opacification of the pulmonary artery with both
conventional iohexol and liposomal-iohexol and allowed detection of pulmonary embolism in
all six rabbits that survived the initial PE induction. Time attenuation curves using the liposomal
contrast agent confirmed a stable plateau phase greater than 100HU that remained stable over
several hours. Figure 1 shows a typical time-attenuation curve for the last rabbit imaged initially
with liposomal contrast agent one hour after conventional contrast to avoid early
contamination. Previous rabbits showed mild, early contamination with conventional contrast
with early peaks in the time-attenuation curves, which then showed a uniformly stable
attenuation above 100 HU for several hours.
When comparing conspicuity of pulmonary embolism, there was very close correlation
between conventional iohexol and liposomal iohexol. Pulmonary emboli were demonstrated
ranging from saddle embolus in the pulmonary trunk down to subsegmental pulmonary arteries.
For measurements, we opted to evaluate the central to segmental branches only. Figures 2 and
3 depict filling defects within the contrast column on two comparable slices through the
pulmonary trunk and main pulmonary arteries for both contrast agents. The liposomal agent
clearly shows better uniformity of contrast enhancement throughout the thoracic vessels, while
the emboli are equally well visualized using both agents.
Thrombolytic effect measurements
Pulmonary emboli were observed in all six animals. One animal remained untreated (control),
while five received t-PA per protocol and clot volumes were measured and plotted over time
(Figure 4). Volumetric analysis showed no change in pulmonary embolism size for the single
untreated (control) rabbit, which died relatively soon following PE induction (curve not
shown). In the five treated animals, one animal showed no significant response, and the volume
measurements were stable (within the measurement error of 8%; rabbit #2). The other four
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rabbits showed clot volume reduction, ranging from 10 – 57%, mean 42% (Figure 4). Figures
5–6 show examples of the observed reduction in the thrombus burden in the main and branch
pulmonary arteries in this rabbit model utilizing the liposomal blood pool agent.
Discussion
The aim of this study was to test the concept of prolonged imaging of the pulmonary arterial
tree using the long circulating liposomal CT contrast agent, and compare the diagnostic quality
to the reference standard of an optimally timed bolus of low-osmolar contrast agent (iohexol).
In particular, we were interested in showing the feasibility of imaging treatment effects in a
thrombolytic pulmonary embolism rabbit model. It appears that the results were positive both
in PE identification and for demonstration of treatment effects. However, several issues need
further discussion.
First, the evaluation of PE partly depends on the size of emboli. In this rabbit model, central
clot is already fairly small when compared to the human pulmonary arteries. Nevertheless, as
the study demonstrated, both conventional and liposomal contrast enhanced CT pulmonary
angiography were successful in outlining filling defects within the pulmonary artery
compatible with embolus. This is along the line of expectations, as previous work has
demonstrated the feasibility of blood pool agents in a rabbit model (10,15).
Second, it was possible to repeat the imaging procedure without the additional need for contrast
agent injection for up to 4 hours. The findings demonstrate a biphasic enhancement pattern
with a equilibration and a plateau phase of the contrast agent, similar to other tested long
circulating and blood pool agents (9,10,18,21). However, our experiment demonstrated a much
longer maintenance of contrast enhancement in the pulmonary arteries, while the contrast
density (in the range of 130 HU) remained at higher values than other agents described thus
far (9–11,18,21). These two essential components enable visualization of the effects of
thrombolytic therapy of the central and lobar pulmonary emboli. In fact, the volume reduction
in the central clot of 40% could be measured, whereas the clots in the lobar vessels improved
significantly (but were too small to measure with confidence).
One of the five treated rabbits showed no significant response to t-PA and the clot size remained
relatively stable. The literature also shows that some patients don’t respond to fibrinolytic
therapy, both in cardiac (22), arterial (23) and venous thromboembolic applications (24). Most
of such studies don’t show effect measurements until 6 – 24 hours following the initial therapy
application. Thus, the fact that we have demonstrated similar findings in this rabbit model
within minutes/hours of drug administration may yield a model that could be applied for novel
drug development and help in gaining more insight into dynamic therapeutic effects within
minutes to hours of drug delivery.
The results of this study have important potential applications for future clinical use. The
prolonged density increase in the vascular space allows for repeated CT imaging without the
need for repeated contrast injections. Combined with the altered clearance mechanism via the
liver and spleen (organs of the reticulo-endothelial system), this is an important break-through
in the pharmacokinetics of iohexol which is not thought to be particularly hepato-toxic
compared to chemotherapeutic liposomes (doxorubicin), however needs to be explicitly
investigated. (25) Altered clearance by liposomal contrast agents may allow contrast studies
in patients with impaired renal function, as well as, multiple combined use of CT in acute
settings, such as for “triple rule out” in the context of patients presenting with acute chest pain.
Another important potential application relates to the use of thrombolytic therapy in myocardial
infarction/acute ischemia and in patients with massive (and potentially submassive) pulmonary
embolism. The application of blood pool agents could determine the effects of such treatment
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over a period of several hours (possibly days), without the risk of nephrotoxicity. Thus, earlier
management decisions would be feasible based on the visualization of treatment response or
lack thereof. This practice has already been evaluated for patients with pulmonary embolism
(17), but these patients required repeated contrast injections and imaging was repeated at
approximately 24 hours post treatment. The use of blood pool agents will allow greater
flexibility, as the nephrotoxic time limitations will no longer be an issue.
Currently, the production of this blood pool agent is limited in capacity to small animals, but
scaling up of this production is currently under-development. Furthermore, the potential
toxicity and clinical safety of this agent is yet to be proven. Nevertheless, these initial in vivo
studies demonstrate the feasibility of performing repeated imaging and the potential
applications are of huge interest. Thus, studies using larger animals will be the next logical
step in the development of this agent for clinical use.
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Figure 1.
This graph depicts a typical time-attenuation curve in the pulmonary artery and aorta over time
with stable attenuation above 100 HU for four hours.
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Figure 2.
These images demonstrate side-by-side comparison of the images in the same rabbit using
conventional versus liposomal iohexol contrast agent. A central pulmonary embolus at the
bifurcation is present (bold arrow) and the key structures are idenfied. Notice that the liposomal
agent gives almost homogeneous contrast in both the right and left sided heart, whereas the
conventional contrast necessitates bolus timing for right sided enhancement.
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Figure 3.
Side-by-side comparison of images in a rabbit following central PE injection, demonstrating
the clot in the left main/lower lobe branch using both conventional and liposomal iohexol
contrast agents (bold arrows). There is a slight difference in slice position, but otherwise there
is excellent correlation both in axial and reconstructed coronal planes.
Burke et al. Page 11
Acad Radiol. Author manuscript; available in PMC 2008 March 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 4.
This graph demonstrates the clot size measurements (% volume from baseline) over time
following injection of t-PA. Rabbit 2 shows no significant response, but the other 4 treated
rabbits show a clot volume decrease in the range of 40–60%.
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Figure 5.
These image series demonstrate clot resolution of a central embolus (bold arrow) in response
to t-PA during a 90-minute interval using liposomal iohexol contrast.
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Figure 6.
These series of images demonstrate near-complete clot resolution of a right lower lobe embolus
(bold arrow) in response to t-PA during a 240-minute interval using liposomal iohexol contrast.
It should be noted that no additional contrast was administered during this time period.
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